Core Insights - K12 has received two Silver Medals from the International Serious Play Awards for its educational games, K12 ELA Village and K12 Coordinate Islands world for Minecraft Education, highlighting its commitment to game-based learning innovations [1][5] Company Overview - K12 has been a national leader in online learning for 25 years, serving over three million students across the United States [2][6] - The company offers flexible learning options, including online public and private schools, personalized tutoring, and accredited homeschool curriculum [6] Educational Innovations - K12 ELA Village is designed for students in Grades 2-5, focusing on the Science of Reading principles to enhance skills in grammar, vocabulary, syntax, and reading comprehension through various mini-games [3] - K12 Coordinate Islands world for Minecraft Education engages Grade 5 students in graphing lessons through an adventure across themed islands, allowing them to navigate coordinate planes and interpret ordered pairs [4] Learning Approach - K12 integrates technology-enabled, standards-aligned gameplay to transform traditional learning into active discovery, making education more interactive and engaging for students [5]

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing n ...

Core Insights - Cogent Biosciences, Inc. presented updated preclinical data on its pan KRAS(ON) inhibitor at the 2025 AACR-NCI-EORTC International Conference, indicating a potential best-in-class profile for its lead molecule [1][2] Group 1: Product Development - The pan KRAS(ON) program aims to file an Investigational New Drug (IND) application with the FDA in 2026 [2] - The presented data highlights the KRAS(ON/OFF) inhibitor CGT1263, which shows selectivity for mutant KRAS over HRAS and NRAS, with picomolar activity across various KRAS mutant cell lines [3] - CGT1815, the prodrug of CGT1263, is designed to enhance human pharmacokinetic performance, demonstrating superior efficacy in tumor growth inhibition studies compared to RMC-6236 [3] Group 2: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [4] - The company is also conducting a Phase 1 study of a novel FGFR2/3 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [4]

—Strategic Shift Focuses on Stablecoin Infrastructure and RWA Track Hong Kong, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SOLOWIN HOLDINGS (NASDAQ: AXG) (“Solowin” or the “Company”), a leading financial services firm bridging traditional and digital assets, today announced the celebration of its first trade under the new ticker symbol “AXG” with a bell-ringing ceremony at the Nasdaq Stock Exchange. The event brought together long-term investors, strategic partners, and senior executives, marking a significant miles ...

Core Points - Clariant's Board of Directors has decided to reduce its size from eleven to eight members to enhance corporate governance and address investor concerns regarding independence, tenure, and gender diversity [1][2] - Five directors will not stand for reelection at the 2026 AGM, and the Board will propose two new independent members ahead of the meeting [1] - The independent Chairman, Ben van Beurden, emphasized the importance of these changes in aligning with the company's strategy and best practices in corporate governance [2] Company Overview - Clariant is a sustainability-focused specialty chemical company based in Switzerland, with a total staff of 10,465 and recorded sales of CHF 4.152 billion in the fiscal year ending December 31, 2024 [7] - The company operates through three business units: Care Chemicals, Catalysts, and Adsorbents & Additives [7]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 24 October 2025) Reference is made to the stock exchange notices published by Hofseth BioCare ASA ("HBC" or the "Company") earlier today regarding the launch of a private placement ...

Core Viewpoint - Hofseth BioCare ASA ("HBC") is planning a private placement of new shares to raise between approximately NOK 155 million and NOK 181 million, aimed at capitalizing on the growing demand for salmon-derived nutrition and expanding its market presence [2][3]. Group 1: Private Placement Details - The private placement will consist of between 86,096,132 and 100,638,889 new shares at a fixed price of NOK 1.80 per share [2]. - Pre-commitments totaling approximately NOK 155 million have already been secured, with NOK 103.4 million in cash and NOK 52 million from debt conversion [2][7]. - The placement will be divided into two tranches, with Tranche 1 consisting of up to 68,555,556 shares and Tranche 2 up to 32,083,333 shares [8]. Group 2: Strategic Use of Proceeds - Proceeds will be allocated to expand the B2B ingredients unit and enhance customer adoption of nutraceutical offerings, particularly in high-growth regions like Asia and the US [3]. - Funds will support initiatives in metabolic health and healthy aging, following recent product successes and increased market interest [4]. - Investment will also focus on scaling the Brilliant Petcare brand, which is experiencing global growth in the premium pet nutrition segment [4]. Group 3: Partnerships and R&D - HBC aims to develop new concepts with global distributor partners and strengthen alliances with contract manufacturers, alongside general corporate purposes and marketing activities [5]. - The company will also allocate funds for further research and development to support its innovation pipeline [5]. Group 4: Divestment and Shareholding - In conjunction with the private placement, HBC will divest shares in AecorBio Inc. for approximately USD 5 million, reflecting a 20% valuation increase from the last funding round [6]. - Post-divestment, HBC will retain approximately 52% ownership in AecorBio [6]. Group 5: Regulatory and Application Process - The application period for the private placement starts on October 24, 2025, and is expected to close by October 27, 2025 [11]. - The completion of the private placement is subject to various conditions, including board resolutions and registration of share capital increases [12][13]. - An extraordinary general meeting (EGM) is expected to be convened around November 20, 2025, to approve the issuance of shares in Tranche 2 [15].

Group 1 - The total number of shares as of September 30, 2025, is 43,203,225 [1] - The total voting rights associated with these shares is 48,979,191, while the exercisable voting rights amount to 48,925,369 [1] - The theoretical number of voting rights includes all shares, even those with suspended voting rights, as per Article 223-11 of the AMF general regulation [1][2] Group 2 - The information regarding voting rights is also accessible in the "Regulated Information" section of the Ipsos website [2]

PRESS RELEASEBrussels, 24 October 2025 (17.45)World leader in aluminium anodising CHANGES IN COIL’S GOVERNANCE COIL, the world leader in aluminium anodising, is reshaping its governance to accelerate its transformation and enhance operational leadership in a challenging market environment. At its meeting on 16 October 2025, the Board of Directors of COIL decided to terminate the contract with Finance & Management International (FMI), represented by Timothy Hutton, which had until now been responsible for th ...

Core Insights - PMV Pharmaceuticals announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial, focusing on rezatapopt for patients with advanced solid tumors harboring a TP53 Y220C mutation [1][4][6] Efficacy Data - The Phase 2 clinical trial data showed a 34% overall response rate (ORR) among 103 evaluable patients, with a median duration of response of 7.6 months [4][5] - In the ovarian cancer cohort, the ORR was 46% among 48 evaluable patients, with a median duration of response of 8.0 months [4][5] - Confirmed responses were observed across eight tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma [4][5] Safety Profile - The safety population included 112 patients treated with rezatapopt at a dose of 2000mg daily, with a median of three prior lines of systemic therapy [5][11] - Treatment-related adverse events (TRAEs) were mostly Grade 1-2, with the most frequent being nausea, fatigue, and increased blood creatinine [11] - The rate of drug discontinuations due to TRAEs was 3.6%, indicating manageable safety [11] Regulatory Plans - The company plans to submit a New Drug Application (NDA) for rezatapopt in the first quarter of 2027 for the treatment of platinum-resistant/refractory ovarian cancer [4][6] About Rezatapopt - Rezatapopt is a first-in-class small molecule designed to reactivate p53 by selectively binding to the p53 Y220C mutant protein, restoring its tumor-suppressor function [7][9] About the PYNNACLE Clinical Trial - The PYNNACLE trial is a Phase 1/2 study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation, with a focus on safety, tolerability, and efficacy [8][9]